Patent: 8,637,014
✉ Email this page to a colleague
Summary for Patent: 8,637,014
| Title: | Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses |
| Abstract: | This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival. |
| Inventor(s): | Rother; Russell P. (Oklahoma City, OK), Faas McKnight; Susan (Old Lyme, CT) |
| Assignee: | Alexion Pharmaceuticals, Inc. (Cheshire, CT) |
| Application Number: | 13/533,546 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,637,014
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Centocor Ortho Biotech Products, L.p. | ORTHOCLONE OKT3 | muromanab-cd3 | Injection | 103463 | 09/14/1992 | ⤷ Try a Trial | 2027-07-25 |
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2027-07-25 |
| Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2027-07-25 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
